Medical Patent News

RSS

Bone Biologics receives Notice of Allowance of patent claims that protects formation of cartilage by UCB-1

Bone Biologics, Inc. announced today that it has received a US Patent Office Notice of Allowance of patent claims which strongly protects the formation of cartilage by the unique NELL 1 protein (UCB-1). Additional claims cover the surgical application of the NELL 1 (UCB-1) protein by several delivery agents.

18 Mar 2010

ImmunoCellular Therapeutics receives Notice of Allowance covering antibodies targeting pancreatic cancer

ImmunoCellular Therapeutics, Ltd., a biotechnology company that is developing immune based therapies for the treatment of various forms of cancer, announced today it received a Notice of Allowance from the United States Patent and Trademark Office covering technology relating to monoclonal antibodies that bind to certain epitopes present on pancreatic cancers. This patent will broaden the Company’s proprietary intellectual property for ICT-109 and ICT-37, two of the Company’s monoclonal antibody product candidates.

17 Mar 2010

Patent applications continue to alter medical landscape to improve patient care

Over the past 40 years, more than 2,400 patents and patent applications-pioneering modern medicine with the devices and drugs that advance minimally invasive treatments-have been filed by members of the Society of Interventional Radiology.

17 Mar 2010

Shire receives Paragraph IV Notice Letter over generic INTUNIV ANDAs from Teva Pharmaceuticals

Shire plc, announces that it has received a Paragraph IV Notice Letter from Teva Pharmaceuticals USA, Inc. advising of the filing of an Abbreviated New Drug Application for a generic version of Shire's 1 mg, 2mg, 3 mg, and 4mg guanfacine hydrochloride extended release tablets, INTUNIV(TM).

17 Mar 2010

USPTO issues Notice of Allowance for Quick-Med Technologies' NIMBUS technology

Quick-Med Technologies, Inc., a leader in developing innovative antimicrobial technologies for the healthcare and consumer markets, announced today that the U.S. Patent and Trademark Office has issued a Notice of Allowance for intellectual property that significantly adds to the current patent coverage for the Company's NIMBUS technology.

17 Mar 2010

Actoplus Met and Actos: Mylan enters into settlement agreements with Takeda Pharmaceutical

Mylan Inc. today announced that it has entered into settlement agreements with Takeda Pharmaceutical Co. related to two treatments for type 2 diabetes: Actoplus Met®, 15 mg/500 mg and 15 mg/850 mg, known generically as Pioglitazone Hydrochloride (HCl) and Metformin HCl Tablets, and Actos®, 15 mg, 30 mg and 45 mg, known generically as Pioglitazone HCl Tablets.

16 Mar 2010

Epeius Biotechnologies' tumor-targeted vaccine technology for cancer immunotherapy receives patent protection

Epeius Biotechnologies Corporation, an emerging leader in the field of targeted genetic medicine, received a notice of allowance from the USPTO for a crucial patent covering its leading tumor-targeted vaccine technology for cancer immunotherapy. The issuance of this valuable patent protection for tumor targeted immunotherapy follows on the heels of two international patents covering targeted gene medicine in the U.S. and Europe, respectively, and places Epeius Biotech at the forefront of these emerging fields of clinical medicine with best-of-breed solutions and incontrovertible proofs-of-principle in the clinic.

16 Mar 2010

AlloSource receives US patent for cleaning and disinfecting system

AlloSource, one of the nation's largest non-profit providers of skin, bone and soft tissue allografts for use in surgical procedures and the world's largest processor of live cellular bone growth substitutes, has been awarded its first patent for a propriety tissue cleaning and disinfecting process called RICA.

16 Mar 2010

Impax Laboratories initiates challenge of patent over generic TRILIPIX

Impax Laboratories, Inc. today confirms that it has initiated a challenge of the patent listed by Abbott Laboratories and Fournier Laboratories Ireland Ltd. in connection with its TRILIPIX® (choline fenofibrate) delayed-release capsules, 135 mg and 45 mg.

15 Mar 2010

Ranbaxy resolves generic Actos patent litigation

Ranbaxy Laboratories Limited, along with its wholly owned subsidiary Ranbaxy Pharmaceuticals Inc. (collectively, "Ranbaxy"), announced today that they have reached an agreement with Takeda Pharmaceutical Company Limited and Takeda Pharmaceuticals North America resolving outstanding patent litigation related to Ranbaxy's generic equivalent version of Actos® (Pioglitazone Hydrochloride) 15 mg, 30 mg and 45 mg tablets.

15 Mar 2010

Neurologix receives US PTO Notice of Allowance concerning treatment approach for epilepsy

Neurologix, Inc. today announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office for intellectual property central to the company’s approach to the treatment of epilepsy. The patent allowance specifically refers to Neurologix’s patent application, “Methods and Compositions for the Treatment of Neurological Disease,” which covers the treatment of seizures associated with temporal lobe epilepsy by direct administration into the brain’s temporal lobe of an AAV vector encoding Neuropeptide Y (NPY).

15 Mar 2010

Generic Focalin XR patent suit: Intellipharmaceutics International announces settlement

Intellipharmaceutics International Inc. today announced that Novartis Pharmaceuticals Corporation and Celgene Corporation have settled their patent suit in the U.S. District Court for the District of New Jersey, and Elan Pharma International Ltd. has settled its patent suit in the U.S. District Court for the District of Delaware, with Intellipharmaceutics Corp., a wholly-owned subsidiary of Intellipharmaceutics International, and its licensee Par Pharmaceutical, Inc. over a generic version of the Attention Deficit Hyperactivity Disorder drug Focalin XR® (dexmethylphenidate hydrochloride).

12 Mar 2010

USPTO issues patent related to Seattle Genetics' ADC technology

Seattle Genetics, Inc. announced today that the U.S. Patent and Trademark Office has issued a patent related to its antibody-drug conjugate (ADC) technology. U.S. Patent No. 7,659,241 covers cleavable linkers and potent auristatin drug payloads used in certain of Seattle Genetics’ ADC programs, most notably brentuximab vedotin (SGN-35), as well as many ADC programs in development by its collaborators.

11 Mar 2010

Cellectis’ 1485475 European patent: EPO confirms revocation of previously granted claims

Precision BioSciences, Inc., today announced that the Opposition Division of the European Patent Office has issued a written decision confirming its November 18, 2009 revocation of the previously granted claims of Cellectis’ European Patent No. 1 485 475.

11 Mar 2010

Smith & Nephew disappointed with jury findings over RENASYS-F Dressing Kit patent litigation

The Advanced Wound Management division of Smith & Nephew, Inc., a subsidiary of Smith & Nephew plc., notes the decision returned today by a jury in the patent litigation brought by Kinetic Concepts Inc. before the U.S. District Court for the Western District of Texas. In that case, the jury found U.S. Patent Nos. 5,645,081 and 7,216,651 to be infringed by Smith & Nephew's RENASYS-F (Foam) Dressing Kit, which delivers Negative Pressure Wound Therapy to patients in need.

11 Mar 2010

Watson Pharmaceuticals resolves Actos patent litigation

Watson Pharmaceuticals, Inc, today announced that it has reached a settlement agreement with Takeda Pharmaceutical Company Limited and Takeda Pharmaceuticals North America resolving outstanding patent litigation related to Watson's generic equivalent version of Actos® (Pioglitazone Hydrochloride) 15mg, 30mg and 45mg tablets.

11 Mar 2010

Kinetic Concepts wins patent infringement case

Kinetic Concepts, Inc. today announced that a United States District Court jury has found that a negative pressure wound therapy (NPWT) product marketed and sold by Smith & Nephew plc (NYSE: SNN) infringes two patents owned by Wake Forest University Health Sciences, which are exclusively licensed to KCI.

11 Mar 2010

Watson Laboratories sued over ANDA filing for generic Opana ER

Watson Pharmaceuticals, Inc., a leading specialty pharmaceutical company, today confirmed that its subsidiary, Watson Laboratories, Inc., has been sued by Endo Pharmaceuticals Inc. and Penwest Pharmaceuticals Co. in connection with the filing of Watson's Abbreviated New Drug Application (ANDA) for Oxymorphone Hydrochloride Extended-Release Tablets, 40mg.

9 Mar 2010

Rexahn Pharmaceuticals granted Japanese patent for Archexin

Rexahn Pharmaceuticals, Inc, a clinical stage pharmaceutical company commercializing potential best in class oncology and CNS therapeutics, today announced that the Japanese Patent Office has issued a patent for its novel anti-cancer compound, Archexin®.

8 Mar 2010

iCAD granted patent covering SecondLook Digital CAD solution incorporating lesion metrics

iCAD, Inc., an industry-leading provider of advanced image analysis and workflow solutions for the early identification of cancer, announces that the United States Patent and Trademark Office recently granted the company Patent Number 7,660,448. This patent covers future iterations of iCAD’s SecondLook® Digital Computer-Aided Detection (CAD) solution with potential application to the company’s other image analysis solutions.

8 Mar 2010

Medical Patent News

Bone Biologics receives Notice of Allowance of patent claims that protects formation of cartilage by UCB-1

ImmunoCellular Therapeutics receives Notice of Allowance covering antibodies targeting pancreatic cancer

Patent applications continue to alter medical landscape to improve patient care

Shire receives Paragraph IV Notice Letter over generic INTUNIV ANDAs from Teva Pharmaceuticals

USPTO issues Notice of Allowance for Quick-Med Technologies' NIMBUS technology

Actoplus Met and Actos: Mylan enters into settlement agreements with Takeda Pharmaceutical

Epeius Biotechnologies' tumor-targeted vaccine technology for cancer immunotherapy receives patent protection

AlloSource receives US patent for cleaning and disinfecting system

Impax Laboratories initiates challenge of patent over generic TRILIPIX

Ranbaxy resolves generic Actos patent litigation

Neurologix receives US PTO Notice of Allowance concerning treatment approach for epilepsy

Generic Focalin XR patent suit: Intellipharmaceutics International announces settlement

USPTO issues patent related to Seattle Genetics' ADC technology

Cellectis’ 1485475 European patent: EPO confirms revocation of previously granted claims

Smith & Nephew disappointed with jury findings over RENASYS-F Dressing Kit patent litigation

Watson Pharmaceuticals resolves Actos patent litigation

Kinetic Concepts wins patent infringement case

Watson Laboratories sued over ANDA filing for generic Opana ER

Rexahn Pharmaceuticals granted Japanese patent for Archexin

iCAD granted patent covering SecondLook Digital CAD solution incorporating lesion metrics

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Latest News